

BioRestorative Therapies shares promising Phase 2 trial results for BRTX-100, showing significant pain reduction and functional improvement in cLDD patients.
You can purchase shares of BioRestorative Therapies (NASDAQ:BRTX) through any online brokerage.
Other companies in BioRestorative Therapies’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
BioRestorative Therapies has a consensus price target of $360.00.
The stock price for BioRestorative Therapies (NASDAQ: BRTX) is $1.1 last updated November 20, 2026 at 5:23 PM EST.
There are no upcoming dividends for BioRestorative Therapies.
BioRestorative Therapies does not have any upcoming earnings scheduled.
There is no upcoming split for BioRestorative Therapies.
BioRestorative Therapies is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called...